{"filing":{"accession_number":"0001764013-26-000100","cik":"0001764013","ticker":"IMVT","company_name":"Immunovant, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"imvt-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/imvt-20260806.htm"},"events":[{"id":25967,"run_id":23581,"accession_number":"0001764013-26-000100","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Immunovant issued a press release on August 6, 2026 announcing financial results for its fiscal first quarter ended June 30, 2026, including condensed consolidated statements of operations and balance sheets. The disclosure reports net loss of $153.2 million, R\u0026D expenses of $142.6 million, cash position of $797.8 million, and clinical development updates for IMVT-1402 across six indications. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.","company_name":"Immunovant, Inc.","ticker":"IMVT","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26920,"accession_number":"0001764013-26-000100","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Immunovant issued a press release on August 6, 2026 announcing financial results for its fiscal first quarter ended June 30, 2026, including condensed consolidated statements of operations and balance sheets. The disclosure reports net loss of $153.2 million, R\u0026D expenses of $142.6 million, cash position of $797.8 million, and clinical development updates for IMVT-1402 across six indications. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:50:50.934140+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26920,"accession_number":"0001764013-26-000100","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Immunovant issued a press release on August 6, 2026 announcing financial results for its fiscal first quarter ended June 30, 2026, including condensed consolidated statements of operations and balance sheets. The disclosure reports net loss of $153.2 million, R\u0026D expenses of $142.6 million, cash position of $797.8 million, and clinical development updates for IMVT-1402 across six indications. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:50:50.934140+00:00","company_name":"Immunovant, Inc.","ticker":"IMVT","filing_date":"2026-08-06"}]}